Last reviewed · How we verify
Janssen Ad26.COV2.S — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Janssen Ad26.COV2.S (Janssen Ad26.COV2.S) — Alvea Holdings, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Janssen Ad26.COV2.S TARGET | Janssen Ad26.COV2.S | Alvea Holdings, LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Janssen Ad26.COV2.S CI watch — RSS
- Janssen Ad26.COV2.S CI watch — Atom
- Janssen Ad26.COV2.S CI watch — JSON
- Janssen Ad26.COV2.S alone — RSS
Cite this brief
Drug Landscape (2026). Janssen Ad26.COV2.S — Competitive Intelligence Brief. https://druglandscape.com/ci/janssen-ad26-cov2-s. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab